Tag: BUHLMANN Quantum Blue Infliximab

The New Biosimilar of IFX SB2 Can be Quantified by IFX-Optimized Therapeutic Drug Monitoring Assays

BÜHLMANN Quantum Blue® Infliximab Citation: Magro, F., Rocha, C. et al. P229 The new biosimilar of infliximab SB2 can be quantified by IFX-optimized therapeutic drug monitoring assays. Journal of Crohns and Colitis. 2018, Jan. DOI: 10.1093/ecco-jcc/jjx180.356. BÜHLMANN Quantum Blue® IFX is for Research Use Only in the US. Not for use in diagnostic procedures in the US. Health Canada

A Pilot Study Using Point of Care Testing for IFX and Faecal Calprotectin in IBD Patients

BÜHLMANN Quantum Blue® Infliximab Citation: Sophie Restellini, Talat Bessissow, Carolyne Lemieux, Che-Yung Chao, Gary Wild, Ernest Seidman, Alain Bitton, Peter L. Lakatos, Waqqas Afif. P711 A pilot study using point of care testing for IFX and faecal calprotectin in IBD patients with a secondary loss of response. Journal of Crohn's and Colitis. 2018 Jan. DOI: 10.1093/ecco-jcc/jjx180.838. Highlight from this

BÜHLMANN Laboratories AG (BL), based in Basel Switzerland, has been discovering, developing & manufacturing innovative chemistry and immunological in-vitro diagnostic (IVD) and research use only (RUO) assays for almost 50 years (circa 1976). As the United States commercial affiliate of BL, BUHLMANN Diagnostics Corp (BDC), based in Amherst, NH is committed to providing exceptional sales, support, and technical services to our clinical, discovery and basic science research laboratory customers.

Tag: BUHLMANN Quantum Blue Infliximab

The New Biosimilar of IFX SB2 Can be Quantified by IFX-Optimized Therapeutic Drug Monitoring Assays

A Pilot Study Using Point of Care Testing for IFX and Faecal Calprotectin in IBD Patients

ABOUT US

SOCIAL MEDIA

QUICK LINKS

CONTACT US